Charles River Laboratories International (CRL) Stock Price
Charles River Laboratories International Price
Over the last 19 years Charles River Laboratories International grew revenue by 7.3% annually, reaching 4.02 B USD. Earnings per share have declined at 13.1% per year over the last 17 years. For Charles River Laboratories International, the net margin of -3.6% is down versus 11.0% a few years ago. The consensus 12-month price target for Charles River Laboratories International is 273.00 USD, about 7.3% below where the stock trades today. Of 23 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 100% above its 52-week low.
Charles River Laboratories International stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Charles River Laboratories International over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Charles River Laboratories International stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Charles River Laboratories International's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Charles River Laboratories International Price |
|---|---|
| 9/24/2026 | 294.44 USD |
| 9/23/2026 | 277.33 USD |
| 9/22/2026 | 287.12 USD |
| 9/21/2026 | 277.51 USD |
| 9/18/2026 | 277.43 USD |
| 9/17/2026 | 281.67 USD |
| 9/16/2026 | 276.83 USD |
| 9/15/2026 | 271.73 USD |
| 9/14/2026 | 271.90 USD |
| 9/11/2026 | 277.43 USD |
| 9/10/2026 | 273.00 USD |
| 9/9/2026 | 278.35 USD |
| 9/8/2026 | 281.65 USD |
| 9/4/2026 | 288.50 USD |
| 9/3/2026 | 293.35 USD |
| 9/2/2026 | 291.76 USD |
| 9/1/2026 | 282.34 USD |
| 8/31/2026 | 288.24 USD |
| 8/30/2026 | 287.10 USD |
| 8/28/2026 | 293.11 USD |
| 8/27/2026 | 301.86 USD |
| 8/26/2026 | 295.10 USD |
| 8/25/2026 | 297.64 USD |
| 8/24/2026 | 295.87 USD |
| 8/21/2026 | 295.19 USD |
| 8/20/2026 | 291.45 USD |
| 8/19/2026 | 289.72 USD |
| 8/18/2026 | 285.31 USD |
| 8/14/2026 | 280.05 USD |
| 8/13/2026 | 281.27 USD |
Charles River Laboratories International Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Charles River Laboratories International Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.36 | 1.68 | 1.86 | 2.27 | 2.62 | 2.92 | 3.54 | 3.98 | 4.13 | 4.05 | 4.02 | 3.91 | 3.99 | 4.18 | 4.49 | 4.70 |
| 5.09 | 23.33 | 10.47 | 22.02 | 15.67 | 11.52 | 21.11 | 12.32 | 3.85 | -1.94 | -0.84 | -2.74 | 2.10 | 4.89 | 7.39 | 4.65 |
| 38.96 | 38.25 | 37.70 | 37.07 | 36.55 | 36.71 | 37.68 | 36.77 | 36.38 | 32.87 | 30.51 | 30.51 | 30.51 | 30.51 | 30.51 | 30.51 |
| 0.53 | 0.64 | 0.70 | 0.84 | 0.96 | 1.07 | 1.33 | 1.46 | 1.50 | 1.33 | 1.23 | 1.19 | 1.22 | 1.28 | 1.37 | 1.43 |
| 0.21 | 0.24 | 0.32 | 0.33 | 0.35 | 0.52 | 0.59 | 0.65 | 0.62 | 0.22 | 0.51 | 0.92 | 1.00 | 1.09 | 1.25 | 1.28 |
| 15.11 | 14.10 | 17.07 | 14.61 | 13.39 | 17.72 | 16.64 | 16.35 | 14.94 | 5.41 | 12.63 | 23.51 | 25.06 | 26.09 | 27.88 | 27.26 |
| 149.00 | 154.00 | 123.00 | 226.00 | 252.00 | 364.00 | 390.00 | 486.00 | 474.00 | 10.00 | -144.00 | 561.00 | 632.00 | 700.00 | 795.00 | 815.00 |
| 18.25 | 3.36 | -20.13 | 83.74 | 11.50 | 44.44 | 7.14 | 24.62 | -2.47 | -97.89 | -1,540.00 | -489.58 | 12.66 | 10.76 | 13.57 | 2.52 |
| 47.42 | 48.27 | 47.34 | 49.21 | 49.87 | 51.03 | 51.56 | 51.38 | 51.62 | 51.14 | 49.22 | 49.22 | 49.22 | 49.22 | 49.22 | 49.22 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Charles River Laboratories International generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Charles River Laboratories International retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Charles River Laboratories International's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Charles River Laboratories International has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Charles River Laboratories International's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Charles River Laboratories International stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Charles River Laboratories International Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Charles River Laboratories International business model & stock analysis
Charles River Laboratories International SWOT Analysis
Strengths
Charles River Laboratories International Inc has established itself as a prominent player in the research and development services industry.
Strong financial performance and consistent revenue growth provide a solid foundation for future expansion and investment.
The company possesses a wide range of capabilities and expertise, offering a comprehensive suite of services to its clients.
Strong reputation and long-standing relationships with key industry partners contribute to a highly trusted brand image.
Weaknesses
Charles River Laboratories International Inc may face potential challenges in integrating newly acquired companies and maintaining consistent quality standards across all operations.
Reliance on a few major clients for a significant portion of revenue could pose a risk to the company's financial stability in case of client attrition.
Limited geographical presence may hinder the company's ability to tap into emerging markets and expand its client base.
The company might face regulatory constraints and compliance issues in the highly regulated industries it serves, increasing operational complexity.
Opportunities
Increasing demand for outsourcing in the pharmaceutical and biotechnology sectors opens up new growth opportunities for Charles River Laboratories International Inc.
Expansion into untapped markets, such as Asia and Latin America, could lead to additional revenue streams and diversification.
Advances in technology and innovation present the opportunity for the company to enhance its services and offer cutting-edge solutions to clients.
Strategic partnerships and collaborations with academic institutions and research organizations can foster innovation and strengthen the company's position in the market.
Threats
Intense competition from other contract research organizations may lead to pricing pressures and reduced market share.
Evolving regulatory landscape and potential changes in government policies could impact the company's operations and profitability.
Economic downturns and fluctuations in research and development budgets of pharmaceutical companies could affect demand for Charles River Laboratories International Inc's services.
Increasing scrutiny on animal testing practices may result in stricter regulations and a potential shift towards alternative testing methods.
Charles River Laboratories International Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Charles River Laboratories International Segments
Charles River Laboratories International Revenue by Segment (1/4)
3 Years
5 Years
Max
Details
Charles River Laboratories International Revenue by Segment (2/4)
Max
Details
Charles River Laboratories International Revenue by Segment (3/4)
3 Years
5 Years
10 Years
Max
Details
Charles River Laboratories International Revenue by Segment (4/4)
3 Years
5 Years
10 Years
Max
Details
Charles River Laboratories International Revenue by Region
3 Years
5 Years
Max
Details
Charles River Laboratories International Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Charles River Laboratories International historical P/E ratio, EBIT multiple, and P/S ratio
Charles River Laboratories International annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Charles River Laboratories International's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Charles River Laboratories International's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Charles River Laboratories International's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Charles River Laboratories International shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Charles River Laboratories International forecasts and price targets in September 2026
Analyst Price Targets 2026Charles River Laboratories International Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/10/2026 | Maintained | Buy | 58 | |
| 8/7/2026 | Maintained | Overweight | 46 | |
| 8/6/2026 | Maintained | Outperform | 48 | |
| 8/6/2026 | Upgrade | NeutralOverweight | 53 | |
| 8/6/2026 | Maintained | Outperform | 62 | |
| 7/20/2026 | Downgrade | OutperformHold | 56 | |
| 7/13/2026 | Maintained | Neutral | 31 | |
| 7/9/2026 | Maintained | Overweight | 46 | |
| 6/17/2026 | Upgrade | Equal WeightOverweight | 46 | |
| 5/29/2026 | Upgrade | HoldOutperform | 56 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Charles River Laboratories International Earnings Calls
Charles River Laboratories International Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/4/2026 | 2.96USD | - | 958.25 MUSD | - | 2026 Q3 |
| 8/5/2026 | 2.74USD | 3.02USD | 977.20 MUSD | - | 2026 Q2 |
| 5/7/2026 | 1.96USD | 2.06USD | 977.46 MUSD | - | 2026 Q1 |
| 2/18/2026 | 2.33USD | 2.39USD | 987.02 MUSD | - | 2025 Q4 |
| 11/5/2025 | 2.32USD | 2.43USD | 987.20 MUSD | - | 2025 Q3 |
| 8/6/2025 | 2.50USD | 3.12USD | 968.92 MUSD | - | 2025 Q2 |
| 2/19/2025 | 2.50USD | 2.66USD | 948.22 MUSD | - | 2024 Q4 |
| 11/6/2024 | 2.42USD | 2.59USD | 975.99 MUSD | - | 2024 Q3 |
| 8/7/2024 | 2.39USD | 2.80USD | 1.02 BUSD | - | 2024 Q2 |
| 5/9/2024 | 2.06USD | 2.27USD | 992.31 MUSD | - | 2024 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Charles River Laboratories International stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Charles River Laboratories International shareholder structure
| % | Name |
|---|---|
11.85399% | |
7.78609% | |
6.97330% | |
6.46075% | |
5.80541% | |
4.83668% |
Charles River Laboratories International Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.63% | SEC ↗ | |
8.60% | SEC ↗ | |
8.60% | SEC ↗ | |
8.60% | SEC ↗ | |
8.60% | SEC ↗ | |
8.50% | SEC ↗ | |
8.20% | SEC ↗ | |
7.38% | SEC ↗ | |
7.00% | SEC ↗ | |
6.90% | SEC ↗ |
Charles River Laboratories International Executives and Management Board
17 members · avg. age 59 · 35 % women
Mr. James Foster (74)
Chairman of the Board, President, Chief Executive Officer · since 1976
13.47 M USD
Management
Ms. Birgit Girshick (55)
Chief Operating Officer, Corporate Executive Vice President
Mr. Joseph LaPlume (51)
Corporate Executive Vice President - Corporate Development and Strategy
Ms. Victoria Creamer (55)
Corporate Executive Vice President, Chief People Officer
Mr. Michael Knell (49)
Interim Chief Financial Officer
Ms. Shannon Parisotto (51)
Corporate Executive Vice President - Discovery and Safety Assessment Management
Mr. Todd Spencer
Corporate Vice President, Investor Relations · since 2024
Board of Directors
Ms. Reshema Kemps-Polanco (52)
Independent Director
Ms. Virginia Wilson (70)
Independent Director
Dr. Martin Mackay (69)
Lead Independent Director
Dr. Nancy Andrews (68)
Independent Director
Mr. George Llado (59)
Independent Director
Dr. Craig Thompson (72)
Independent Director
Charles River Laboratories International Supply Chain
Charles River Laboratories International Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.81 | 0.86 | 0.92 | ||
| 2 | 0.88 | 0.88 | 0.91 | ||
| 3 | 0.71 | 0.66 | 0.85 | ||
| 4 | 0.55 | 0.68 | 0.79 | ||
| 5 | -0.56 | -0.54 | 0.57 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.55 | -0.52 | — | ||
| 2 | -0.88 | -0.92 | — | ||
| 3 | 0.19 | 0.07 | -0.56 | ||
| 4 | -0.88 | -0.04 | -0.41 | ||
| 5 | First Wave Biopharma | 0.87 | 0.62 | -0.31 |
Frequently asked questions about Charles River Laboratories International
The business model of Charles River Laboratories International Inc primarily revolves around providing research and development (R&D) solutions and services to the pharmaceutical, biotechnology, and medical device companies. As a leading contract research organization (CRO), the company offers a wide range of preclinical and clinical laboratory services, including safety assessment, discovery support, manufacturing support, and laboratory animal research services. Charles River Laboratories operates on a fee-for-service basis, collaborating with its clients to accelerate drug discovery, development, and commercialization processes. With a focus on quality, reliability, and scientific expertise, the company aims to support its clients in advancing their scientific research and achieving their business goals.
Charles River Laboratories International Inc is primarily active in the life sciences industry.
Some of the main competitors of Charles River Laboratories International Inc in the market include Covance Inc., Envigo, PPD, Eurofins Scientific, and LabCorp.
Charles River Laboratories International Inc is a renowned company in the field of preclinical and clinical laboratory services. Founded in 1947, Charles River has built a strong reputation as a trusted provider of comprehensive research support. With a focus on helping pharmaceutical and biotechnology companies bring new drugs to market, they offer a wide range of services including drug discovery, safety assessment, and manufacturing support to clients worldwide. The company's expertise in advanced animal models, laboratory sciences, and support services has propelled it to the forefront of the life sciences industry. Today, Charles River Laboratories continues to play a vital role in advancing much-needed medical therapies.
Charles River Laboratories International Inc has achieved several significant milestones. It has consistently demonstrated strong financial performance, delivering consistent revenue growth and expanding its global footprint. The company has successfully completed strategic acquisitions, enabling it to enhance its capabilities and expand its service offerings. Charles River Laboratories International Inc has also received notable recognition, including being named one of the World's Most Ethical Companies for several consecutive years. Moreover, the company has been at the forefront of scientific advancements, collaborating with global pharmaceutical and biotechnology companies to develop innovative solutions that improve drug discovery and development processes.
Charles River Laboratories International Inc is primarily present in the following countries and regions: United States, Canada, Europe, Asia Pacific, and Latin America.
Charles River Laboratories International Inc represents various values and corporate philosophies. The company is committed to their mission of improving the lives of people and animals through innovative research and development. They aim to maintain the highest standards of scientific integrity, ethical conduct, and regulatory compliance. Charles River Laboratories prioritizes collaboration and partnership with their clients to provide comprehensive solutions and exceptional service. With a focus on quality, efficiency, and expertise, they strive to consistently deliver reliable and innovative scientific services and products. Through their dedication to responsible and sustainable practices, Charles River Laboratories aims to make a positive impact on society and the environment.
Analysts currently set an average price target of 267.60 USD for the Charles River Laboratories International stock (median: 273.00 USD), implying -3.5 % versus the latest price. The consensus is based on 23 analyst ratings.
Charles River Laboratories International Analyst Price Targets 2026
23 analysts currently rate the Charles River Laboratories International stock: 17 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Charles River Laboratories International to generate revenue of 3.91 B USD and earnings per share of 11.41 USD.
Charles River Laboratories International Analyst Price Targets 2026
Converted at the current exchange rate, the Charles River Laboratories International share trades at 258.72 EUR (294.44 USD).
The Charles River Laboratories International share (CRL) is listed on 6 stock exchanges, including: NYSE (CRL), SIX (Zürich) (RV6.SW), XETRA (RV6.DE), Frankfurt (RV6.F), München (RV6.MU), Düsseldorf (RV6.DU).
Charles River Laboratories International Inc is a global leader in the field of life sciences, offering its customers a wide range of products and services. The company's business model is based on three main areas: research and development, preclinical services, and bioproducts. Research and Development: Charles River Laboratories offers a variety of services to support its customers in the development of new products. These include chemical and pharmacological screening systems, study design and planning, cell and tissue banking, genotoxicology, protein and antibody production, and much more. Charles River Laboratories has a comprehensive range of scientific and technical capabilities to assist its customers in the development of new drugs, biotechnology products, and medical devices. Preclinical Services: The company provides its customers with a wide range of preclinical services to test the safety and efficacy of products. These services include toxicology, pathology, pharmacology, bioanalytics, and clinical diagnostics. Charles River Laboratories has several preclinical research facilities worldwide and can support customers in the validation of new therapies and products. Bioproducts: Charles River Laboratories produces a variety of bioproducts for research and development, including cell lines, antibodies, nucleic acids, and proteins. The company also offers specialized services such as genetic manipulation and custom modification of cell lines to achieve specific research goals. The company focuses on customer loyalty and has earned the trust of customers by offering high-quality products and services. Charles River Laboratories has a global presence with facilities in North America, Europe, and Asia, and can serve customers worldwide. The company also maintains a strong partnership with the scientific community by supporting research initiatives and public health measures. Charles River Laboratories is committed to offering its customers a comprehensive range of services to meet their needs in the field of life sciences. The company is dedicated to continuously improving its research and development and introducing new services and products to meet the ever-changing needs of customers.
The expected revenue of Charles River Laboratories International is 3.91 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Charles River Laboratories International is 561.66 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Charles River Laboratories International is currently 25.80. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Charles River Laboratories International stock.
The price-to-sales ratio (P/S) of Charles River Laboratories International is currently 3.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Charles River Laboratories International stock.
The Eulerpool Quality Score for Charles River Laboratories International is 3/10.
The ISIN of Charles River Laboratories International is US1598641074. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Charles River Laboratories International is 939391. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Charles River Laboratories International is CRL. The ticker symbol is used to trade Charles River Laboratories International shares on the stock exchange.
Charles River Laboratories International paid dividends every year for the past 0 years.
Charles River Laboratories International is assigned to the 'Health' sector.
The dividends of Charles River Laboratories International are distributed in USD.
Charles River Laboratories International stock
Charles River Laboratories International Peer Group
Charles River Laboratories International Ticker
Charles River Laboratories International FIGI
All fundamentals and in-depth analysis of Charles River Laboratories International
Our stock analysis for Charles River Laboratories International stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Charles River Laboratories International. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.